颅内动脉粥样硬化相关闭塞的血栓切除结局
该系统综述与荟萃分析纳入1967例大血管闭塞患者(ICAS-O 496例,非ICAS-O 1471例),比较两组危险因素与血栓切除结局。ICAS-O组合并高血压、糖尿病、血脂异常及吸烟史的比例更高,心房颤动比例更低;术中再闭塞、补救性球囊血管成形与颅内支架置入更多,穿刺至再灌注时间更长,但最终再通、症状性颅内出血、良好功能结局与死亡率无统计学差异。
要点
- ICAS-O患者高血压、糖尿病、血脂异常、吸烟史更常见,心房颤动更少。
- ICAS-O术中再闭塞率更高,常需补救性球囊扩张或颅内支架。
- ICAS-O穿刺至再灌注时间更长,但最终再通与功能结局与非ICAS-O相当。
核心结论
- ICAS-O患者具有独特的危险因素谱,血管内再灌注治疗面临特有的技术挑战。
研究设计与样本
- 系统综述与荟萃分析,纳入1967例患者,其中ICAS-O 496例、非ICAS-O 1471例。
主要发现
- ICAS-O组高血压患病率显著更高(OR 1.46;95% CI 1.10-1.93)。
- ICAS-O组糖尿病患病率显著更高(OR 1.68;95% CI 1.29-2.20)。
- ICAS-O组血脂异常患病率显著更高(OR 1.94;95% CI 1.04-3.62)。
- ICAS-O组吸烟史显著更多(OR 2.11;95% CI 1.40-3.17),心房颤动显著更少(OR 0.20;95% CI 0.13-0.31)。
- ICAS-O组术中再闭塞率更高(OR 23.7;95% CI 6.96-80.7),补救性球囊血管成形(OR 9.49;95% CI 4.11-21.9)与补救性颅内支架置入(OR 14.9;95% CI 7.64-29.2)更多。
关键数值与推荐
- 穿刺至再灌注时间ICAS-O组80.8分钟、非ICAS-O组55.5分钟,平均差21.3分钟(95% CI 11.3-31.3)。
- 最终再通(mTICI 2b/3)无统计学差异(OR 0.67;95% CI 0.36-1.27)。
- 症状性颅内出血无统计学差异(OR 0.79;95% CI 0.50-1.24)。
- 良好功能结局(mRS 0-2)无统计学差异(OR 1.16;95% CI 0.85-1.58)。
- 死亡率无统计学差异(OR 0.94;95% CI 0.64-1.39)。
临床怎么用
- 对ICAS-O患者应预期术中再闭塞与补救治疗需求,可考虑动脉内糖蛋白IIb/IIIa抑制剂输注、球囊血管成形与颅内支架置入以实现再血管化。
局限性
- 原文摘要未报告纳入研究的异质性、发表偏倚及随访时长等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Intracranial atherosclerosis (ICAS) is an important cause of large vessel occlusion and poses unique challenges for emergent endovascular thrombectomy. The risk factor profile and therapeutic outcomes of patients with ICAS-related occlusions (ICAS-O) are unclear. We performed a systematic review and meta-analysis of studies reporting the clinical features and thrombectomy outcomes of large vessel occlusion stroke secondary to underlying ICAS (ICAS-O) versus those of other causes (non-ICAS-O). Methods- A literature search on thrombectomy for ICAS-O was performed. Random-effect meta-analysis was used to analyze the prevalence of stroke risk factors and outcomes of thrombectomy between ICAS-O and non-ICAS-O groups. Results- A total of 1967 patients (496 ICAS-O and 1471 non-ICAS-O) were included. The ICAS-O group had significantly higher prevalence of hypertension (odds ratio [OR] 1.46; 95% CI, 1.10-1.93), diabetes mellitus (OR, 1.68; 95% CI, 1.29-2.20), dyslipidemia (OR, 1.94; 95% CI, 1.04-3.62), smoking history (OR, 2.11; 95% CI, 1.40-3.17) but less atrial fibrillation (OR, 0.20; 95% CI, 0.13-0.31) than the non-ICAS-O group. About thrombectomy outcomes, ICAS-O had higher intraprocedural reocclusion rate (OR, 23.7; 95% CI, 6.96-80.7), need for rescue balloon angioplasty (OR, 9.49; 95% CI, 4.11-21.9), rescue intracranial stenting (OR, 14.9; 95% CI, 7.64-29.2), and longer puncture-to-reperfusion time (80.8 versus 55.5 minutes, mean difference 21.3; 95% CI, 11.3-31.3). There was no statistical difference in the rate of final recanalization (modified Thrombolysis in Cerebral Infarction score of 2b/3; OR, 0.67; 95% CI, 0.36-1.27), symptomatic intracerebral hemorrhage (OR, 0.79; 95% CI, 0.50-1.24), good functional outcome (modified Rankin Scale score of 0-2; OR, 1.16; 95% CI, 0.85-1.58), and mortality (OR, 0.94; 95% CI, 0.64-1.39) between ICAS-O and non-ICAS-O. Conclusions- Patients with ICAS-O display a unique risk factor profile and technical challenges for endovascular reperfusion therapy. Intraprocedural reocclusion occurs in one-third of patients with ICAS-O. Intraarterial glycoprotein IIb/IIIa inhibitors infusion, balloon angioplasty, and intracranial stenting may be viable rescue treatment to achieve revascularization, resulting in comparable outcomes to non-ICAS-O.
引用
- Tsang ACO, Orru E, Klostranec JM, et al. Thrombectomy Outcomes of Intracranial Atherosclerosis-Related Occlusions. Stroke. 2019. PMID: 31084327. doi:10.1161/STROKEAHA.119.024889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。